|
2026
|
G/S
|
Non-medicated toilet preparations and skin care products, cosmetic and beauty preparations, cosme... |
|
|
G/S
|
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal prep... |
|
|
G/S
|
Non-medicated toilet preparations and skin care products; cosmetic and beauty preparations; cosme... |
|
|
G/S
|
Pharmaceutical preparations and gene therapy products in the nature of injectable biological prep... |
|
|
G/S
|
Pharmaceutical preparations. |
|
2025
|
G/S
|
Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à sa... |
|
|
G/S
|
Analgesics; Anti-inflammatories; Topical analgesic creams; Analgesic balm; Pharmaceutical prepara... |
|
|
G/S
|
Analgesics; Anti-inflammatories; Pharmaceutical preparations for the treatment of pain and pain r... |
|
|
G/S
|
Downloadable mobile application for patient education and training in the use and administration ... |
|
|
Invention
|
Engineered heterodimeric proteins.
The present invention provides heterodimeric antibodies and f... |
|
|
Invention
|
Gripper.
The invention relates to a gripper comprising a gripper body. The gripper body extends ... |
|
|
Invention
|
Pharmaceutical products and stable liquid compositions of il-17 antibodies.
The disclosure is di... |
|
|
G/S
|
Foot deodorant spray; Non-medicated foot lotions; Antiperspirants; Cosmetic preparations |
|
|
Invention
|
Methods of using factor b inhibitors.
Described herein are methods of treating paroxysmal noctur... |
|
|
Invention
|
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor.
The invention pr... |
|
|
Invention
|
Use of labeled inhibitors of prostate specific membrane antigen (psma), as agents for the treatme... |
|
|
Invention
|
Prostate specific membrane antigen (psma) ligands and uses thereof.
The present disclosure relat... |
|
|
Invention
|
Identifying patient response to s1p receptor modulator administration.
The invention provides a ... |
|
|
Invention
|
Hydroquinazoline derivatives for the treatment of a disease or disorder. The disclosure relates t... |
|
|
Invention
|
Hydroquinazoline derivatives and treatment of a disease or disorder using the same. The disclosur... |
|
|
Invention
|
Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor.
Th... |
|
|
Invention
|
Synthesis and crystalline forms of a cdk2 inhibitor. The invention generally relates to crystalli... |
|
|
Invention
|
Uses of a cdk2 inhibitor in the treatment of cancer. The invention relates to a pharmaceutical co... |
|
|
Invention
|
Methods of making chimeric antigen receptor-expressing cells.
The disclosure provides methods of... |
|
|
Invention
|
Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d). The prese... |
|
|
Invention
|
Synthesis of a precursor of radiopharmaceutical products. The present disclosure is directed to a... |
|
|
Invention
|
Aminoisoquinoline compounds and methods of using thereof. The present invention relates to a comp... |
|
|
Invention
|
Double stranded rnai agents, compositions and methods of use.
Disclosed are, inter alia, double ... |
|
|
Invention
|
Double stranded rnai agents, compositions and methods of use. Disclosed are, inter alia, double s... |
|
|
Invention
|
Double stranded rnai agents, compositions and methods of use. Disclosed are, inter alia, therapeu... |
|
|
Invention
|
Chimeric antigen receptors and uses thereof.
The invention provides immune effector cells (for e... |
|
|
Invention
|
7h-pyrrolo[2,3-d]pyrimidine derivatives as cyclin-dependent kinase inhibitors useful for the trea... |
|
|
Invention
|
Cyclin-dependent kinase inhibitors.
The invention relates to compounds which inhibit Cyclin-Depe... |
|
|
Invention
|
Angiopoietin-like protein 4 antibody-based treatment. Methods, kits, and compositions are provide... |
|
|
Invention
|
Treatment of systemic sclerosis using anti-baff-r antibodies. The disclosure relates to methods, ... |
|
|
Invention
|
Lipid-modified nucleic acid compounds and methods.
Disclosed herein, inter alia, are lipid-modif... |
|
|
Invention
|
Cd19 and cd22 chimeric antigen receptors and uses thereof.
The present disclosure provides compo... |
|
|
Invention
|
Dosing regimens for n-(3-cyano-5-(cyclohexylmethyl)-6,6-dimethyl-4,5,6,7-tetrahydrothieno[3,2-c]p... |
|
|
Invention
|
Fgf21 mimetic antibodies and uses thereof.
The present disclosure relates to monoclonal antibodi... |
|
|
Invention
|
Dosage regimen of an s1p receptor modulator.
S1P receptor modulators are administered following ... |
|
|
Invention
|
Method for reducing the risk of a cardiovascular event with conjugated antisense compounds target... |
|
|
Invention
|
Hydroquinazoline derivatives for the treatment of a disease or disorder.
The disclosure relates ... |
|
|
Invention
|
Novel pharmaceutical composition.
The invention pertains to dispersible tablets comprising as ac... |
|
|
Invention
|
Binding molecules against bcma and uses thereofprivate view.
The present disclosure provides BCM... |
|
|
Invention
|
Optimized lentiviral transfer vectors and uses thereof.
The invention features lentiviral transf... |
|
|
Invention
|
Antibody molecules to lag-3 and uses thereof.
Antibody molecules that specifically bind to LAG-3... |
|
|
Invention
|
Immune effector cell therapies with enhanced efficacy.
The present invention relates generally t... |
|
|
Invention
|
Cell-based assay for measuring drug product potency.
The invention relates to the an in vitro qu... |
|
2024
|
Invention
|
Shp inhibitor compositions and uses for chimeric antigen receptor therapy.
Compositions and meth... |
|
|
Invention
|
Nucleic acid ligation method. The present disclosure relates to biocatalytic ligation methods for... |
|
2023
|
Invention
|
Nucleic acid ligation method.
The present disclosure relates to biocatalytic ligation methods fo... |
|
|
Invention
|
Amorphous solid dispersions comprising naporafenib.
The present invention relates to the field o... |
|
|
Invention
|
Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention.
The present ... |
|
|
Invention
|
(s)-engineered oxynitrilase polypeptides and uses thereof.
The present disclosure relates to a p... |
|
|
Invention
|
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof.
Anti-EphA2 antibody-... |
|
|
Invention
|
Antibody-drug conjugates of antineoplastic compounds and methods of use thereof.
Antibody-drug c... |
|
|
Invention
|
Novel recombinant aav vp2 fusion polypeptides.
This disclosure relates to adeno-associated virus... |
|
2022
|
Invention
|
Combination therapy of radionuclide complex.
The present disclosure is directed to a method of t... |
